
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Cytosorbents Crp (CTSO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CTSO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $5
1 Year Target Price $5
1 | Strong Buy |
0 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.46% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 77.01M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 2 | Beta 1.05 | 52 Weeks Range 0.71 - 1.61 | Updated Date 06/29/2025 |
52 Weeks Range 0.71 - 1.61 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -45.59% | Operating Margin (TTM) -44.54% |
Management Effectiveness
Return on Assets (TTM) -20.46% | Return on Equity (TTM) -96.26% |
Valuation
Trailing PE - | Forward PE 7.73 | Enterprise Value 92400210 | Price to Sales(TTM) 2.18 |
Enterprise Value 92400210 | Price to Sales(TTM) 2.18 | ||
Enterprise Value to Revenue 2.62 | Enterprise Value to EBITDA -1.92 | Shares Outstanding 62610400 | Shares Floating 54315127 |
Shares Outstanding 62610400 | Shares Floating 54315127 | ||
Percent Insiders 15.29 | Percent Institutions 27.77 |
Analyst Ratings
Rating 2 | Target Price 5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cytosorbents Crp

Company Overview
History and Background
CytoSorbents Corporation, founded in 2002, focuses on critical care immunotherapy through blood purification. Its initial focus was on removing inflammatory mediators in sepsis, expanding to address other critical conditions.
Core Business Areas
- Critical Care: Develops and commercializes blood purification therapies for sepsis, acute respiratory distress syndrome (ARDS), and other critical illnesses. CytoSorb is their flagship product.
- Cardiac Surgery: Offers blood purification technologies to mitigate inflammation during and after cardiac surgery.
- Antithrombotic Removal: Develops products to remove antithrombotic drugs from the body in emergency situations, such as during bleeding complications.
Leadership and Structure
Philip P. Chan is the CEO. The company has a board of directors and is structured with departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- CytoSorb: CytoSorb is a blood purification cartridge designed to remove excessive cytokines and other inflammatory mediators from the bloodstream. It is used in sepsis, ARDS, and other critical illnesses. CytoSorb has achieved regulatory approvals in the European Union and other countries. The market share is variable and dependent on region and indication, making it difficult to provide a precise figure. Key competitors include companies offering CRRT (Continuous Renal Replacement Therapy) and other blood purification techniques. Competitors for this include Baxter (BAX) and Fresenius Medical Care (FMS).
- Ecosorb: Ecosorb is a blood purification cartridge designed to remove ticagrelor, a common antithrombotic drug. It aims to reverse antiplatelet effects in emergency situations such as bleeding complications. Exact market share data not publicly available due to it being a relatively new segment. Potential competitors could include other reversal agents if developed and approved.
Market Dynamics
Industry Overview
The blood purification market is driven by increasing rates of sepsis, ARDS, and other critical illnesses. Advances in technology and growing awareness of blood purification therapies contribute to market growth.
Positioning
CytoSorbents is positioned as a leader in blood purification for critical care, particularly in cytokine removal and antithrombotic reversal. Its competitive advantages lie in its CytoSorb technology and growing portfolio of products.
Total Addressable Market (TAM)
The estimated total addressable market (TAM) is in the billions of dollars, encompassing critical care, cardiac surgery, and antithrombotic removal applications. Cytosorbents is positioning itself to capture a significant share of this market, particularly with its Cytosorb and Ecosorb products
Upturn SWOT Analysis
Strengths
- Proprietary CytoSorb technology
- Regulatory approvals in EU and other countries
- Expanding product portfolio
- Strong research and development efforts
- Experienced management team
Weaknesses
- Limited commercial presence in the US
- Dependence on key products like CytoSorb
- Relatively small size compared to major players in blood purification
- Funding and cashflow management
- Geographic concentration of sales
Opportunities
- Expansion into the US market
- Development of new blood purification therapies
- Partnerships with major healthcare providers
- Increased adoption of blood purification in critical care
- New regulatory approval for new products
Threats
- Competition from established players in blood purification
- Regulatory hurdles
- Pricing pressures
- Technological advancements by competitors
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- BAX
- FMS
- NXTM
Competitive Landscape
Cytosorbents Crp faces competition from larger, more established players in the blood purification market. Its competitive advantages include its proprietary CytoSorb technology and focus on critical care immunotherapy. However, competitors have greater resources and wider product portfolios.
Major Acquisitions
Medica S.p.A. CARDIOSORB business
- Year: 2023
- Acquisition Price (USD millions): 3.3
- Strategic Rationale: The acquisition of the CARDIOSORB business expands Cytosorbents' portfolio in cardiac surgery and provides access to new markets and technologies.
Growth Trajectory and Initiatives
Historical Growth: Cytosorbents Crp has experienced significant revenue growth in recent years, driven by increasing adoption of CytoSorb and expanding geographic reach.
Future Projections: Analysts project continued revenue growth, driven by expansion into the US market and development of new products. Growth is projected to be 15%-20% per year for the next 3-5 years.
Recent Initiatives: Recent initiatives include expanding the US sales force, initiating clinical trials for new indications, and strategic partnerships with healthcare providers.
Summary
Cytosorbents is a small-cap company with a leading product in blood purification, but it faces stiff competition from larger companies. While Cytosorb has achieved regulatory success in Europe and other countries, its US market presence remains limited. Revenue growth has been strong; however, profitability remains elusive and requires careful monitoring. Expansion into the US market and the development of new products are critical for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
- CytoSorbents Investor Relations
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cytosorbents Crp
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2013-11-07 | CEO & Director Dr. Phillip P. Chan M.D., Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 149 | Website https://www.cytosorbents.com |
Full time employees 149 | Website https://www.cytosorbents.com |
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.